qsymia
Qsymia - Innovative Medication for Weight Loss
Qsymia is used in the United States for weight loss by reducing appetite and controlling cravings for sugars and carbohydrates. Studies have demonstrated that individuals taking Qsymia achieved at least 5% weight loss within 8 weeks, along with significant improvements in metabolic markers such as blood sugar and lipid levels. Qsymia is not registered in Israel and is available through special authorization for weight management.
- Age 18 or older.
- BMI (Body Mass Index) of 30 or higher, defined as severe obesity.
- BMI (Body Mass Index) of 27 or higher, defined as overweight, provided there is at least one additional obesity-related risk factor, such as diabetes, high blood pressure, elevated blood lipid levels, etc.
What is the mechanism of action of Qsymia?
Qsymia contains a combination of two medications: Phentermine and Topiramate, both of which are approved by the U.S. Food and Drug Administration (FDA).
Phentermine acts similarly to amphetamines by stimulating the sympathetic nervous system. It promotes the release of the neurotransmitter norepinephrine in the brain, thereby increasing the level of the hormone leptin. Leptin, in turn, suppresses appetite and enhances feelings of fullness after meals.

Topiramate, on the other hand, was initially developed as an anti-seizure medication, but researchers later discovered that one of its additional effects is appetite suppression and increased feelings of fullness. Although the exact mechanism by which topiramate contributes to weight loss is still not completely understood, studies have shown it influences the neurotransmitter GABA, which plays a role in regulating appetite and feelings of fullness after meals. Additionally, topiramate inhibits enzymes known as carbonic anhydrase, thereby slowing down processes responsible for producing fats in the body, such as triglycerides.
The uniqueness of Qsymia lies in combining two active ingredients that operate through different mechanisms, as well as its extended-release formulation, typically allowing for just one capsule to be taken per day.
What are the results of studies examining Qsymia?
Two large, long-term clinical studies (involving 3,754 participants, lasting 56 weeks) examined the effectiveness and safety of Qsymia. All participants had a BMI of 27 or higher, and the medication was combined with diet and exercise.
In the first study \[1], involving 1,267 men and women with a BMI ranging from 35 to 79, participants taking the highest dose of Qsymia lost an average of 10.9% of their body weight. Participants on the lower initial dose lost about 5.1%, whereas those in the placebo group (diet and exercise alone) lost only 1.6% of their body weight.
The study data also showed that a greater proportion of participants taking Qsymia achieved meaningful weight loss:
- 47% of those on the higher dose and 19% on the lower dose lost at least 10% of their body weight.
- Additionally, 67% of those on the higher dose and 45% on the lower dose lost at least 5.1% of their body weight.

Another interesting finding is that participants taking the higher dose of Qsymia lost at least 5% of their body weight as early as 8 weeks into the study. They also experienced significant improvements in metabolic indicators, such as blood sugar and lipid levels.
In the second study \[2], researchers examined 2,487 participants with a BMI of 27-45, each with at least two additional weight-related health conditions. Participants taking the maximum dose of Qsymia reduced their body weight by an average of 9.8%. Those on the lower initial dose lost about 7.8%, whereas participants in the placebo group, treated with diet and exercise alone, lost only 1.2% of their body weight.
According to the study data, a greater proportion of participants taking Qsymia achieved significant weight loss:
- 48% of participants on the higher dose and 37% on the lower dose lost at least 10% of their body weight.
- Additionally, 70% of participants on the higher dose and 62% on the lower dose lost at least 5.1% of their body weight.
Another interesting point worth noting: Participants in both dosage groups (higher and lower) achieved a weight loss of at least 5% within just 8 weeks of starting the study.
The Multidisciplinary Approach to Obesity Treatment
The most effective method for weight loss through medication is a personalized treatment plan, supported and monitored by a multidisciplinary team of experts.
Various clinical studies \[4,5] conducted in recent years have shown that the most successful approach to weight loss combines individually tailored medications at adjustable dosages, including medication combinations, with medical supervision and ongoing nutritional follow-up by a clinical dietitian within a structured treatment framework. This process significantly improves patient adherence and supports long-term weight maintenance.
The Obesity Treatment Center offers a comprehensive multidisciplinary weight loss program combined with medication-based treatment. This program includes:
Combined Treatment
Personal Guidance
Diagnosis
Personal Follow-Up
Reducing Side Effects
Continuity of Care
Personally Guided Nutritional Program
Lifestyle Habits
טבלת קליקים וויגובי - כל המינונים
Wegovy 0.25mg
| Wegovy 0.25mg | |
| מינון | קליק |
| 0.006 | 1 |
| 0.013 | 2 |
| 0.02 | 3 |
| 0.027 | 4 |
| 0.033 | 5 |
| 0.04 | 6 |
| 0.047 | 7 |
| 0.054 | 8 |
| 0.06 | 9 |
| 0.067 | 10 |
| 0.074 | 11 |
| 0.081 | 12 |
| 0.087 | 13 |
| 0.094 | 14 |
| 0.1 | 15 |
| 0.108 | 16 |
| 0.114 | 17 |
| 0.121 | 18 |
| 0.128 | 19 |
| 0.135 | 20 |
| 0.141 | 21 |
| 0.148 | 22 |
| 0.155 | 23 |
| 0.168 | 24 |
| 0.168 | 25 |
| 0.175 | 26 |
| 0.182 | 27 |
| 0.189 | 28 |
| 0.195 | 29 |
| 0.202 | 30 |
| 0.209 | 31 |
| 0.216 | 32 |
| 0.222 | 33 |
| 0.229 | 34 |
| 0.236 | 35 |
| 0.243 | 36 |
| 0.25 | 37 |
Wegovy 0.5mg
| Wegovy 0.5mg | |
| מינון | קליק |
| 0.0135 | 1 |
| 0.027 | 2 |
| 0.0405 | 3 |
| 0.0541 | 4 |
| 0.0676 | 5 |
| 0.0811 | 6 |
| 0.0946 | 7 |
| 0.1081 | 8 |
| 0.1216 | 9 |
| 0.1351 | 10 |
| 0.1486 | 11 |
| 0.1622 | 12 |
| 0.1757 | 13 |
| 0.1892 | 14 |
| 0.2027 | 15 |
| 0.2162 | 16 |
| 0.2297 | 17 |
| 0.2432 | 18 |
| 0.2568 | 19 |
| 0.2703 | 20 |
| 0.2838 | 21 |
| 0.2973 | 22 |
| 0.3108 | 23 |
| 0.3243 | 24 |
| 0.3378 | 25 |
| 0.3514 | 26 |
| 0.3649 | 27 |
| 0.3784 | 28 |
| 0.391 | 29 |
| 0.405 | 30 |
| 0.418 | 31 |
| 0.432 | 32 |
| 0.445 | 33 |
| 0.459 | 34 |
| 0.472 | 35 |
| 0.486 | 36 |
| 0.5 | 37 |
Wegovy 1mg
| Wegovy 1mg | |
| מינון | קליק |
| 0.013 | 1 |
| 0.026 | 2 |
| 0.04 | 3 |
| 0.053 | 4 |
| 0.066 | 5 |
| 0.08 | 6 |
| 0.093 | 7 |
| 0.106 | 8 |
| 0.12 | 9 |
| 0.133 | 10 |
| 0.146 | 11 |
| 0.16 | 12 |
| 0.173 | 13 |
| 0.186 | 14 |
| 0.2 | 15 |
| 0.213 | 16 |
| 0.226 | 17 |
| 0.24 | 18 |
| 0.253 | 19 |
| 0.266 | 20 |
| 0.28 | 21 |
| 0.293 | 22 |
| 0.306 | 23 |
| 0.32 | 24 |
| 0.333 | 25 |
| 0.346 | 26 |
| 0.36 | 27 |
| 0.373 | 28 |
| 0.386 | 29 |
| 0.4 | 30 |
| 0.413 | 31 |
| 0.426 | 32 |
| 0.44 | 33 |
| 0.453 | 34 |
| 0.466 | 35 |
| 0.48 | 36 |
| 0.493 | 37 |
| 0.506 | 38 |
| 0.52 | 39 |
| 0.533 | 40 |
| 0.546 | 41 |
| 0.56 | 42 |
| 0.573 | 43 |
| 0.586 | 44 |
| 0.6 | 45 |
| 0.613 | 46 |
| 0.626 | 47 |
| 0.64 | 48 |
| 0.653 | 49 |
| 0.666 | 50 |
| 0.693 | 51 |
| 0.693 | 52 |
| 0.706 | 53 |
| 0.72 | 54 |
| 0.733 | 55 |
| 0.746 | 56 |
| 0.76 | 57 |
| 0.773 | 58 |
| 0.786 | 59 |
| 0.8 | 60 |
| 0.813 | 61 |
| 0.826 | 62 |
| 0.84 | 63 |
| 0.853 | 64 |
| 0.866 | 65 |
| 0.88 | 66 |
| 0.893 | 67 |
| 0.906 | 68 |
| 0.92 | 69 |
| 0.933 | 70 |
| 0.946 | 71 |
| 0.96 | 72 |
| 0.973 | 73 |
| 0.986 | 74 |
| 1 | 75 |
Wegovy 1.7mg
| Wegovy 1.7mg | |
| מינון | קליק |
| 0.022 | 1 |
| 0.045 | 2 |
| 0.068 | 3 |
| 0.09 | 4 |
| 0.113 | 5 |
| 0.136 | 6 |
| 0.158 | 7 |
| 0.181 | 8 |
| 0.204 | 9 |
| 0.226 | 10 |
| 0.249 | 11 |
| 0.272 | 12 |
| 0.294 | 13 |
| 0.317 | 14 |
| 0.34 | 15 |
| 0.362 | 16 |
| 0.385 | 17 |
| 0.408 | 18 |
| 0.43 | 19 |
| 0.453 | 20 |
| 0.476 | 21 |
| 0.498 | 22 |
| 0.521 | 23 |
| 0.544 | 24 |
| 0.566 | 25 |
| 0.589 | 26 |
| 0.612 | 27 |
| 0.634 | 28 |
| 0.657 | 29 |
| 0.68 | 30 |
| 0.702 | 31 |
| 0.725 | 32 |
| 0.748 | 33 |
| 0.77 | 34 |
| 0.793 | 35 |
| 0.816 | 36 |
| 0.838 | 37 |
| 0.861 | 38 |
| 0.884 | 39 |
| 0.906 | 40 |
| 0.929 | 41 |
| 0.952 | 42 |
| 0.974 | 43 |
| 0.997 | 44 |
| 1.02 | 45 |
| 1.04 | 46 |
| 1.065 | 47 |
| 1.088 | 48 |
| 1.11 | 49 |
| 1.133 | 50 |
| 1.156 | 51 |
| 1.178 | 52 |
| 1.201 | 53 |
| 1.224 | 54 |
| 1.246 | 55 |
| 1.269 | 56 |
| 1.292 | 57 |
| 1.314 | 58 |
| 1.337 | 59 |
| 1.36 | 60 |
| 1.382 | 61 |
| 1.405 | 62 |
| 1.428 | 63 |
| 1.45 | 64 |
| 1.473 | 65 |
| 1.496 | 66 |
| 1.518 | 67 |
| 1.541 | 68 |
| 1.564 | 69 |
| 1.586 | 70 |
| 1.609 | 71 |
| 1.632 | 72 |
| 1.654 | 73 |
| 1.677 | 74 |
| 1.7 | 75 |
Wegovy 2.4mg
| Wegovy 2.4mg | |
| מינון | קליק |
| 0.032 | 1 |
| 0.064 | 2 |
| 0.096 | 3 |
| 0.128 | 4 |
| 0.16 | 5 |
| 0.192 | 6 |
| 0.224 | 7 |
| 0.256 | 8 |
| 0.288 | 9 |
| 0.32 | 10 |
| 0.352 | 11 |
| 0.384 | 12 |
| 0.416 | 13 |
| 0.448 | 14 |
| 0.48 | 15 |
| 0.512 | 16 |
| 0.544 | 17 |
| 0.576 | 18 |
| 0.608 | 19 |
| 0.64 | 20 |
| 0.672 | 21 |
| 0.704 | 22 |
| 0.736 | 23 |
| 0.768 | 24 |
| 0.8 | 25 |
| 0.832 | 26 |
| 0.864 | 27 |
| 0.896 | 28 |
| 0.928 | 29 |
| 0.96 | 30 |
| 0.992 | 31 |
| 1.024 | 32 |
| 1.056 | 33 |
| 1.088 | 34 |
| 1.12 | 35 |
| 1.152 | 36 |
| 1.184 | 37 |
| 1.216 | 38 |
| 1.248 | 39 |
| 1.28 | 40 |
| 1.312 | 41 |
| 1.344 | 42 |
| 1.376 | 43 |
| 1.408 | 44 |
| 1.44 | 45 |
| 1.472 | 46 |
| 1.504 | 47 |
| 1.536 | 48 |
| 1.568 | 49 |
| 1.6 | 50 |
| 1.632 | 51 |
| 1.664 | 52 |
| 1.696 | 53 |
| 1.728 | 54 |
| 1.76 | 55 |
| 1.792 | 56 |
| 1.824 | 57 |
| 1.856 | 58 |
| 1.888 | 59 |
| 1.92 | 60 |
| 1.952 | 61 |
| 1.984 | 62 |
| 2.016 | 63 |
| 2.048 | 64 |
| 2.08 | 65 |
| 2.112 | 66 |
| 2.144 | 67 |
| 2.176 | 68 |
| 2.208 | 69 |
| 2.24 | 70 |
| 2.272 | 71 |
| 2.304 | 72 |
| 2.336 | 73 |
| 2.368 | 74 |
| 2.4 | 75 |
מונג'רו / מאונג'רו טבלת קליקים - מינונים
Mounjaro 2.5mg
| מונג’רו 2.5mg | |
| מינון | קליק |
| 0.0417 | 1 |
| 0.0833 | 2 |
| 0.125 | 3 |
| 0.1667 | 4 |
| 0.2083 | 5 |
| 0.25 | 6 |
| 0.2917 | 7 |
| 0.3333 | 8 |
| 0.375 | 9 |
| 0.4167 | 10 |
| 0.5 | 12 |
| 0.625 | 15 |
| 0.75 | 18 |
| 0.8333 | 20 |
| 1 | 24 |
| 1.25 | 30 |
| 1.5 | 36 |
| 1.6667 | 40 |
| 2 | 48 |
| 2.5 | 60 |
Mounjaro 5mg
| מונג’רו 5mg | |
| קליק | מינון |
| 1 | 0.0833 |
| 2 | 0.1667 |
| 3 | 0.25 |
| 4 | 0.3333 |
| 5 | 0.4167 |
| 6 | 0.5 |
| 7 | 0.5833 |
| 8 | 0.6667 |
| 9 | 0.75 |
| 10 | 0.8333 |
| 12 | 1 |
| 15 | 1.25 |
| 18 | 1.5 |
| 20 | 1.6667 |
| 24 | 2 |
| 30 | 2.5 |
| 36 | 3 |
| 40 | 3.3333 |
| 48 | 4 |
| 60 | 5 |
Mounjaro 15mg
| מונג’רו 15mg | |
| קליק | מינון |
| 1 | 0.25 |
| 2 | 0.5 |
| 3 | 0.75 |
| 4 | 1 |
| 5 | 1.25 |
| 6 | 1.5 |
| 7 | 1.75 |
| 8 | 2 |
| 9 | 2.25 |
| 10 | 2.5 |
| 12 | 3 |
| 15 | 3.75 |
| 18 | 4.5 |
| 20 | 5 |
| 24 | 6 |
| 30 | 7.5 |
| 36 | 9 |
| 40 | 10 |
| 48 | 12 |
| 60 | 15 |
Mounjaro 7.5mg
| מונג’רו 7.5mg | |
| קליק | מינון |
| 1 | 0.125 |
| 2 | 0.25 |
| 3 | 0.375 |
| 4 | 0.5 |
| 5 | 0.625 |
| 6 | 0.75 |
| 7 | 0.875 |
| 8 | 1 |
| 9 | 1.125 |
| 10 | 1.25 |
| 12 | 1.5 |
| 15 | 1.875 |
| 18 | 2.25 |
| 20 | 2.5 |
| 24 | 3 |
| 30 | 3.75 |
| 36 | 4.5 |
| 40 | 5 |
| 48 | 6 |
| 60 | 7.5 |
Mounjaro 10mg
| מונג’רו 10mg | |
| קליק | מינון |
| 1 | 0.1667 |
| 2 | 0.3333 |
| 3 | 0.5 |
| 4 | 0.6667 |
| 5 | 0.8333 |
| 6 | 1 |
| 7 | 1.1667 |
| 8 | 1.3333 |
| 9 | 1.5 |
| 10 | 1.6667 |
| 12 | 2 |
| 15 | 2.5 |
| 18 | 3 |
| 20 | 3.3333 |
| 24 | 4 |
| 30 | 5 |
| 36 | 6 |
| 40 | 6.6667 |
| 48 | 8 |
| 60 | 10 |
Mounjaro 12.5mg
| מונג’רו 12.5mg | |
| קליק | מינון |
| 1 | 0.2083 |
| 2 | 0.4167 |
| 3 | 0.625 |
| 4 | 0.8333 |
| 5 | 1.0417 |
| 6 | 1.25 |
| 7 | 1.4583 |
| 8 | 1.6667 |
| 9 | 1.875 |
| 10 | 2.0833 |
| 12 | 2.5 |
| 15 | 3.125 |
| 18 | 3.75 |
| 20 | 4.1667 |
| 24 | 5 |
| 30 | 6.25 |
| 36 | 7.5 |
| 40 | 8.3333 |
| 48 | 10 |
| 60 | 12.5 |
Frequently Asked Questions (FAQ)
At the beginning of treatment, your doctor will determine your weekly dosage of Qsymia.
Take one Qsymia capsule daily, preferably at the same time each day, and on an empty stomach.
As with any medication, treatment with Qsymia may cause side effects; however, most are mild and typically subside within days to weeks. Common side effects include tingling sensations, dizziness, changes in taste, and insomnia.
It's important to remember that your healthcare provider, especially if specialized in obesity management, can provide guidance on how to significantly reduce or even prevent these side effects. Real-time adjustments to your medication, including dosage changes and careful monitoring when combined with other medications, can improve treatment adherence and significantly decrease dropout rates among patients.
Rare side effects may include increased resting heart rate, difficulties concentrating, vision changes, the onset of depression or other mood disorders, and occasionally suicidal thoughts or behaviors.
Qsymia should not be used by individuals with glaucoma, hyperthyroidism, or by patients who have experienced a heart attack or stroke within the past 6 months before starting the medication. Additionally, it must not be used by individuals currently taking antidepressants from the MAO inhibitor group.
Pregnant women cannot initiate treatment with Qsymia due to risks of birth defects. Women of childbearing age must avoid becoming pregnant during treatment with Qsymia. For this reason, monthly pregnancy tests via blood samples are required throughout the entire treatment period to ensure they are not pregnant.
The medication has not yet been approved for use in Israel. Once approved, pricing policies and coverage of Qsymia will be determined by health maintenance organizations (HMOs) and various insurance providers.
The information on this page does not replace medical consultation or serve as a basis for diagnosis. For detailed information regarding the medication, please refer to the patient information leaflet as approved by the Ministry of Health. For any additional questions, please consult your healthcare provider or pharmacist.